KURA — Kura Oncology
Median target
$25
calls from the last 12 months
Implied return
+113.3%
median target vs. price
Coverage
9 analysts · 9 calls
updated in the last 12 months
Consensus
8/1/0+8 net
Buy / Hold / Sell
Which analysts are behind KURA's consensus?
See every current rating, price target and the analysts' track records for Kura Oncology — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 9 analysts with calls on KURA updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
KURA elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-08-24 | Insiders | Wilson Troy EdwardPresident and CEO | Insider purchase | 100.0K sh @ $12.39 | $1.2M |
| 2026-08-21 | Insiders | Powl Brian T.Chief Commercial Officer | Insider sale | 4.3K sh @ $11.89 · planned trade | $52K |
| 2026-08-19 | Insiders | Bair Teresa BrophyChief Legal Officer | Insider sale | 31.5K sh @ $12.63 · planned trade | $398K |
| 2026-08-17 | Insiders | Wilson Troy EdwardPresident and CEO | Insider purchase | 100.0K sh @ $11.12 | $1.1M |
| 2022-12-12 | Congress | Christopher L. JacobsNY-NY27 | Purchase | since trade -10.9%, vs market -111.0% | $1K–$15K |
More: congressional trades on KURA · insider activity · executive branch · trending